POLICY BRIEFINGS
Hart Health Strategies provides a comprehensive policy briefing on a weekly basis. This in-depth health policy briefing is sent out at the beginning of each week. The health policy briefing recaps the previous week and previews the week ahead. It alerts clients to upcoming congressional hearings, newly introduced bills, regulatory announcements, and implementation activity related to the Patient Protection and Affordable Care Act (PPACA) and other health laws.
THIS WEEK'S BRIEFING - APRIL 13, 2020
- Senate at Stalemate Over Small Business Stimulus
- Democrats Work to Formulate COVID Phase Four Details
- Legislators Seek to Boost COVID-Related Product Availability
- Cassidy, Shaheen Ask CMS to Revise Interest Rate on Advance Payments
- GOP Doctors Caucus Seeks Additional Provider Relief
- Lawmakers Oversee COVID Testing Accuracy, Availability
- Democratic Members Raise Privacy Concerns Re: COVID Surveillance Network
- Hart Health Strategies COVID-19 Resources
- Wyden Releases Maternal Mortality Report
- Lawmakers Request Investigation into Nursing Homes Use of Psychotropic Drugs
- Recently Introduced Health Legislation
Senate at Stalemate Over Small Business Stimulus
The Senate ended last week without a deal on additional federal aid for small businesses in the midst of the coronavirus pandemic. GOP leadership hoped to pass an amendment to the Coronavirus Aid, Relief, and Economic Security (CARES) Act by unanimous consent that would have provided a $251 billion increase for the Paycheck Protection Program (PPP). Democrats blocked the attempt, arguing that state and local governments as well as hospitals face a more immediate need for federal aid. They also cited the need to improve the PPP loan process for small businesses. Their counteroffer to the GOP interim stimulus package included the addition of $100 billion for hospitals, community health centers, health systems, and for the production and distribution of rapid COVID testing and personal protective equipment (PPE), as well as $150 billion for state and local governments. It would have channeled half of the additional funding for small businesses through community-based and other financial institutions that serve farmers, families, women, minorities, and veterans. The Democratic plan also called for the Administration to report to Congress every 30 days about its distribution of coronavirus testing and supplies across the country. Senate Republicans have said that they will not negotiate over the PPP interim legislation.
Democrats Work to Formulate COVID Phase Four Details
House Speaker Nancy Pelosi (D-Calif.) stated last week that the next coronavirus relief bill will total at least $1 trillion and will focus on replenishing programs, like the Paycheck Protection Program (PPP), established in the $2.2 trillion Coronavirus Aid, Relief, and Economic Security (CARES) Act. She has said that phase four should also include additional direct payments to individuals and strengthen unemployment insurance. A group of 16 Democratic freshman are also urging Speaker Pelosi to include legislative changes to the Affordable Care Act (ACA) in the next coronavirus response bill. The lawmakers propose that the Take Responsibility for Workers and Families Act (H.R. 1868), which would increase the size of premium tax credits for low and middle-income Americans, and the State Health Care Premium Reduction Act (H.R. 1425), which would advance reinsurance policies, be added to the stimulus package currently being negotiated.
Senate Minority Leader Chuck Schumer (D-N.Y.) released his latest COVID response legislation last week. The bill includes the provision of hazard pay for health care providers and other essential workers, as well as the creation of monetary incentives for people who join the medical workforce during the pandemic. The “Heroes Fund” plan would add $13 per hour, up to a total of $25,000, in hazard payments for health care workers, and $15,000 to recruit additional providers to the medical workforce. Hazard payments would be limited for professionals earning above $200,000. The proposal does not yet have bipartisan support from any congressional Republicans.
Legislators Seek to Boost COVID-Related Product Availability
The House Oversight and Reform Committee released documents last week revealing that the Strategic National Stockpile (SNS) has nearly depleted its supply of N95 respirators, surgical masks, face shields, and other personal protective equipment (PPE) used to protect health workers treating COVID-19 patients. The documents indicate that approximately 90 percent of the PPE inventory in the stockpile has been distributed to state and local governments. A spokesperson for the U.S. Department of Health and Human Services (HHS) says that the remaining 10 percent will be kept in reserve for federal response efforts.
House Armed Services Chair Adam Smith (D-Wash.) wants the Department of Defense (DOD) to begin mass producing coronavirus tests and is looking to include provisions to increase production of test swabs in the upcoming fiscal year (FY) 2021 defense authorization bill. The Committee is expected to have the defense authorization legislation drafted by May 1. Rep. Smith also stated that he is in talks with House Speaker Nancy Pelosi (D-Calif.) about including funding to strengthen the Pentagon’s response to the pandemic in the phase four rescue package.
Senate Finance Chair Chuck Grassley (R-Iowa) and Sen. Amy Klobuchar (D-Minn.) sent a letter to Attorney General William Barr urging the Department of Justice (DOJ) to take action to protect consumers from price gouging during the COVID-19 pandemic. The lawmakers believe that the Department should aggressively enforce the President’s March 23 executive order to prevent such conduct and ask for information about what is being done to address the problem of bad actors hoarding items such as essential medical supplies during the coronavirus outbreak. House Energy and Commerce Oversight Subcommittee Chair Diana DeGette (D-Colo.) has called on the Food and Drug Administration (FDA) to address the hoarding of hydroxychloroquine- and chloroquine-based medications. These products, which are normally prescribed to treat lupus and rheumatoid arthritis, have been endorsed by the President as a possible treatment for COVID-19. Rep. Mark Pocan (D-Wis.), Co-Chair of the House Progressive Caucus, has also sent a letter to the FDA Commissioner, questioning whether the administration is aware of any potential shortages for drugs that patients may require when they are put on ventilators. The letter cites a report from Vox News that shortages of sedatives are imminent.
House Ways and Means Chair Richard Neal (D-Mass.) and Sen. Grassley are requesting that that International Trade Commission (ITC) investigate the imports necessary for treating COVID-19 and responding to the pandemic. They assert that a report containing this information would assist lawmakers and the U.S. Trade Representative in proposing or taking appropriate action in regard to the crisis. to The committee leaders request a response from ITC no later than April 30.
April 13, 2020: | Page 1 Page 2 Page 3
SERVICES
- Strategy & Planning
- Information & Counsel
- Washington Presence & Influence
- Materials Development
- Grassroots Advocacy
- Partnership & Coalition Building
- Communications
BRIEFING ARCHIVE
- 2023
- - November 2023
- 11/27/23 VIEW | PRINTABLE PDF
- 11/20/23 VIEW | PRINTABLE PDF
- 11/13/23 VIEW | PRINTABLE PDF
- 11/6/23 VIEW | PRINTABLE PDF
- + October 2023
- + September 2023
- + August 2023
- + July 2023
- + June 2023
- + May 2023
- + April 2023
- + March 2023
- + February 2023
- + January 2023